A data-augmentation method for infectious disease incidence data from close contact groups

Computational Statistics and Data Analysis

Volumn 51, Issue 12, 2007, Pages 6582-6595

  Yang, Yang ^a   Longini Jr , Ira M ^a,b   Elizabeth Halloran, M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiviral agent; Data augmentation; EM algorithm; Infectious disease; Intervention efficacy; Linear model; MLE

Indexed keywords

ALGORITHMS; COMPUTER SIMULATION; DISEASES; ITERATIVE METHODS; MAXIMUM LIKELIHOOD ESTIMATION;

ANTIVIRAL AGENTS; DATA AUGMENTATION; EM ALGORITHM; INFECTIOUS DISEASES; INTERVENTION EFFICACY; LINEAR MODELS;

DATA REDUCTION;

EID: 34547173729     PISSN: 01679473     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.csda.2007.03.007     Document Type: Article

References (28)

1. Addy C.L., Longini I.M., and Haber M.J. A generalized stochastic model for the analysis of infectious disease final size data. Biometrics 47 (1991) 961-974
2. Becker N.G., and Hasofer A.M. Estimation in epidemics with incomplete observations. J. Roy. Statist. Soc. Ser. B 59 (1997) 415-429
3. Becker N.G., Britton T., and O'Neill P.D. Estimating vaccine effects on transmission of infection from household outbreak data. Biometrics 59 (2003) 467-475
4. Cauchemez S., Carrat F., Viboud C., Valleron A.J., and Boëlle P.Y. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Statist. Med. 23 (2004) 3469-3487
5. Datta S., Halloran M.E., and Longini I.M. Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household. Biometrics 55 (1999) 792-798
6. Dempster A.P., Laird N.M., and Rubin D.B. Maximum likelihood from incomplete data via the EM algorithm. J. Roy. Statist. Soc. Ser. B 39 (1977) 1-38
7. Donner A. Some aspects of the design and analysis of cluster randomized trials. Statist. Med. 47 (1998) 95-113
8. Elveback L.R., Fox J.P., and Ackerman E. An influenza simulation model for immunization studies. Amer. J. Epidemiol. 103 (1976) 152-165
9. Germann T.C., Kadau K., Longini I.M., and Macken C.A. Mitigation strategies for pandemic influenza in the United States. Proc. Nat. Acad. Sci. USA 103 (2006) 5935-5940
10. Halloran M.E., Struchiner C.J., and Longini I.M. Study designs for different efficacy and effectiveness aspects of vaccination. Amer. J. Epidemiol. 146 (1997) 789-803
11. Halloran M.E., Préziosi M.-P., and Chu H. Estimating vaccine efficacy from secondary attack rates. J. Amer. Statist. Assoc. 98 (2003) 38-46
12. Halloran M.E., Hayden F.G., Yang Y., Longini I.M., and Monto A.S. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Amer. J. Epidemiol. 165 (2006) 212-222
13. Hayden F.G. Perspectives on antiviral use during pandemic influenza. Philos. Trans. Roy. Soc. London, Ser. B Biol. Sci. 356 (2001) 1877-1884
14. Hayden, F.G., Gubareva, L.V., Monto, A.S., Klein, T.C., Elliott, M.J., Hammond, J.M., Sharp, S.J., Ossi, M.J., Zanamivir Family Study Group (2000). Inhaled zanamivir for the prevention of influenza in families. New England J. Med. 343, 1282-1289.
15. Longini I.M., and Halloran M.E. A frailty mixture model for estimating vaccine efficacy. J. Roy. Statist. Soc. Ser. C 45 (1996) 165-173
16. Longini I.M., and Koopman J.S. Household and community transmission parameters from final distributions of infections in households. Biometrics 38 (1982) 115-126
17. Longini I.M., Halloran M.E., Nizam A., and Yang Y. Containing pandemic influenza with antiviral agents. Amer. J. Epidemiol. 159 (2004) 623-633
18. Longini I.M., Nizam A., Xu S., Ungchusak K., Hanshaoworakul W., Cummings D.A.T., and Halloran M.E. Containing pandemic influenza at the source. Science 309 (2005) 1083-1087
19. Louis T.A. Finding the observed information matrix when using the EM algorithm. J. Roy. Statist. Soc. Ser. B 44 (1982) 226-233
20. Magder L., and Brookmeyer R. Analysis of infectious disease data from partner studies with unknown source of infection. Biometrics 49 (1993) 1110-1116
21. Monto A.S., Pichichero M.E., Blanckenberg S.J., Ruuskanen O., Cooper C., Fleming D.M., and Kerr C. Zanamivir prophylaxis: An effective strategy for the prevention of influenza types A and B within households. J. Infectious Diseases 186 (2002) 1582-1588
22. O'Neill P., and Roberts G.O. Bayesian inference for partially observed stochastic epidemics. J. Roy. Statist. Soc. Ser. A 162 (1999) 121-129
23. O'Neill P., Balding D.J., Becker N.G., Eerola M., and Mollison D. Analyses of infectious disease data from household outbreaks by Markov chain Monte Carlo methods. J. Roy. Statist. Soc. Ser. C 49 (2000) 517-542
24. Paap R. What are the advantages of MCMC based inference in latent variable models?. Statist. Neerlandica 56 (2002) 2-22
25. Rampey A.H., Longini I.M., Haber M.J., and Monto A.S. A discrete-time model for the statistical analysis of infectious disease incidence data. Biometrics 48 (1992) 117-128
26. Reilly M., and Lawlor E. A likelihood-based method for identifying contaminated lots of blood product. Internat. J. Epidemiol. 28 (1999) 787-792
27. van Dyk D.A., and Meng X. The art of data augmentation. J. Comput. Graphical Statist. 10 (2001) 1-50
28. Yang Y., Longini I.M., and Halloran M.E. Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups. J. Roy. Statist. Soc. Ser. C 55 (2006) 317-330